• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氨氯吡咪和螺内酯钾对非氮质血症肝硬化腹水患者疗效的随机临床研究

Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites.

作者信息

Angeli P, Dalla Pria M, De Bei E, Albino G, Caregaro L, Merkel C, Ceolotto G, Gatta A

机构信息

Department of Clinical Medicine, University of Padua, Italy.

出版信息

Hepatology. 1994 Jan;19(1):72-9.

PMID:8276370
Abstract

Although some clinical studies seem to prove the efficacy of nonantialdosteronic potassium-sparing diuretics in the treatment of ascites, no controlled study has compared the efficacy of these drugs with that of antialdosteronic diuretics. Forty nonazotemic cirrhotic patients were randomized to receive amiloride (group A, n = 20) or potassium canrenoate (group B, n = 20). The initial doses of amiloride and potassium canrenoate were 20 mg and 150 mg, respectively. The doses were increased in stepwise fashion to 60 and 500 mg/day, respectively, if no response ensued. Nonresponders to the highest doses of each drug were later treated with potassium canrenoate and amiloride, respectively. Seven of 20 group A patients responded to amiloride, whereas 14 of 20 group B patients responded to potassium canrenoate (p < 0.025). Seven of 13 nonresponders to amiloride later responded to potassium canrenoate, whereas only two of the nonresponders to potassium canrenoate later responded to amiloride. The diuretic responses to amiloride and potassium canrenoate were related to the activity of the renin-aldosterone system. All responders to amiloride (n = 9) had normal values of plasma aldosterone. All nonresponders to amiloride who later responded to potassium canrenoate (n = 7) had increased levels of plasma aldosterone. Moreover, on comparison of all responders (n = 21) and nonresponders (n = 12) to potassium canrenoate, a higher degree of renal proximal sodium reabsorption (with consequent limitation of sodium delivery to the distal tubule) was found to be the main difference.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

尽管一些临床研究似乎证明了非醛固酮类保钾利尿剂在腹水治疗中的疗效,但尚无对照研究比较这些药物与醛固酮拮抗剂的疗效。40例非氮质血症肝硬化患者被随机分为接受阿米洛利治疗组(A组,n = 20)或坎利酸钾治疗组(B组,n = 20)。阿米洛利和坎利酸钾的初始剂量分别为20 mg和150 mg。如果没有反应,剂量分别逐步增加至60 mg和500 mg/天。对每种药物最高剂量无反应者随后分别改用坎利酸钾和阿米洛利治疗。A组20例患者中有7例对阿米洛利有反应,而B组20例患者中有14例对坎利酸钾有反应(p < 0.025)。13例对阿米洛利无反应者中有7例后来对坎利酸钾有反应,而对坎利酸钾无反应者中只有2例后来对阿米洛利有反应。对阿米洛利和坎利酸钾的利尿反应与肾素-醛固酮系统的活性有关。所有对阿米洛利有反应者(n = 9)血浆醛固酮值正常。所有后来对坎利酸钾有反应的阿米洛利无反应者(n = 7)血浆醛固酮水平升高。此外,比较所有对坎利酸钾有反应者(n = 21)和无反应者(n = 12)发现,较高程度的近端肾小管钠重吸收(从而限制钠向远端小管的输送)是主要差异。(摘要截选至250字)

相似文献

1
Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites.氨氯吡咪和螺内酯钾对非氮质血症肝硬化腹水患者疗效的随机临床研究
Hepatology. 1994 Jan;19(1):72-9.
2
A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.非氮质血症肝硬化患者腹水利尿治疗阶梯式护理方法中对螺内酯无反应的病理生理学解释。
Hepatology. 1991 Aug;14(2):231-6.
3
[Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].[长期服用坎利酸钾治疗肝硬化腹水效果的对照研究]
Minerva Med. 1986 Jan 28;77(3-4):87-91.
4
Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites.鉴别利尿剂无应答者与不良长期临床结局:176 例非氮质血症性肝硬化合并中等量腹水患者的 1 年随访。
Clin Sci (Lond). 2011 Dec;121(11):509-21. doi: 10.1042/CS20110018.
5
Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.螺内酯与坎利酸钾的比较临床研究。双交叉随机评估。
Arzneimittelforschung. 1988 Oct;38(10):1492-5.
6
Aldosterone receptor blockade inhibits increased furosemide-sensitive sodium reabsorption in rats with liver cirrhosis.
J Pharmacol Exp Ther. 1998 Dec;287(3):931-6.
7
[Use of canrenoate potassium given orally in ascitogenic cirrhosis].口服坎利酸钾在腹水型肝硬化中的应用
Minerva Dietol Gastroenterol. 1984 Jul-Sep;30(3):273-80.
8
Spironolactone and canrenoate: different antialdosteronic diuretic agents.螺内酯和坎利酸钾:不同的抗醛固酮利尿剂。
Hepatology. 1991 May;13(5):999-1000.
9
Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis.抗醛固酮药物坎利酸钾对肝硬化腹水发生率和静脉曲张进展的影响。
Clin Gastroenterol Hepatol. 2006 Nov;4(11):1395-402. doi: 10.1016/j.cgh.2006.06.005. Epub 2006 Aug 22.
10
Systemic nitric oxide production and renal function in nonazotemic human cirrhosis: a reappraisal.非氮质血症期人类肝硬化患者的全身一氧化氮生成与肾功能:重新评估
Am J Gastroenterol. 2002 Sep;97(9):2383-90. doi: 10.1111/j.1572-0241.2002.05992.x.

引用本文的文献

1
Update on the Complications and Management of Liver Cirrhosis.肝硬化并发症与管理的最新进展
Med Sci (Basel). 2025 Feb 5;13(1):13. doi: 10.3390/medsci13010013.
2
CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.克罗地亚门静脉高压诊断与治疗指南。
Acta Clin Croat. 2024 Apr;63(1):214-243. doi: 10.20471/acc.2024.63.01.26.
3
Ascites: Under- and Overfill: Is Amiloride the Answer?腹水:充盈不足与过度充盈:氨氯吡脒是答案吗?
J Am Soc Nephrol. 2024 Nov 1;35(11):1453-1455. doi: 10.1681/ASN.0000000000000493. Epub 2024 Sep 11.
4
Epithelial Na Channels Function as Extracellular Sensors.上皮钠通道作为细胞外传感器发挥作用。
Compr Physiol. 2024 Mar 29;14(2):1-41. doi: 10.1002/cphy.c230015.
5
Epithelial Na + Channel Activation after Bile Duct Ligation with Mineralocorticoid Receptor Blockade.胆管结扎联合盐皮质激素受体阻断后上皮钠通道的激活
J Am Soc Nephrol. 2024 Nov 1;35(11):1466-1477. doi: 10.1681/ASN.0000000000000442. Epub 2024 Jul 10.
6
Asia-Pacific association for study of liver guidelines on management of ascites in liver disease.亚太肝脏研究协会肝病腹水管理指南
Hepatol Int. 2023 Aug;17(4):792-826. doi: 10.1007/s12072-023-10536-7. Epub 2023 May 26.
7
Exploration of sodium homeostasis and pharmacokinetics in bile duct-ligated rats treated by anti-cirrhosis herbal formula plus spironolactone.抗肝硬化中药复方联合螺内酯治疗胆管结扎大鼠钠稳态及药代动力学的研究
Front Pharmacol. 2023 Jan 18;14:1092657. doi: 10.3389/fphar.2023.1092657. eCollection 2023.
8
Bile acids regulate the epithelial Na channel in native tissues through direct binding at multiple sites.胆汁酸通过在多个位点直接结合调节天然组织中的上皮钠通道。
J Physiol. 2022 Nov;600(21):4695-4711. doi: 10.1113/JP283318. Epub 2022 Sep 23.
9
Hyponatremia in Cirrhosis.肝硬化伴低钠血症。
Clin Liver Dis. 2022 May;26(2):149-164. doi: 10.1016/j.cld.2022.01.001. Epub 2022 Apr 1.
10
Management of Ascites in Patients with Cirrhosis: An Update.肝硬化患者腹水的管理:最新进展
J Clin Med. 2021 Nov 10;10(22):5226. doi: 10.3390/jcm10225226.